Ionis Pharmaceuticals, Inc.
NASDAQIonis Pharmaceuticals heads into its July 29 earnings window with a notable shift in tone: short sellers have been covering and options traders have turned more bullish than they've been in months, yet the stock at $75.99 still sits nearly 40% below the analyst consensus target. The clearest change this week is in positioning. Short interest has dropped 4% over the past five days…
Snapshot as of 24 Jun 2026
Ionis Pharmaceuticals heads into its July 29 earnings window with a notable shift in tone: short sellers have been covering and options traders have turned more bullish than they've been in months, yet the stock at…
Ionis Pharmaceuticals enters the back half of June with an interesting split: analyst conviction is rising, targets are moving higher, yet short sellers have been adding quietly and the stock has slipped 2% on the week…
Ionis Pharmaceuticals heads into the week after Q1 earnings with a notable divergence: the Street is growing more bullish while shorts are methodically unwinding, leaving the stock's $74.83 close roughly 25% below…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IONS — free to start on ORTEX.
Sign up for free →Open IONS on ORTEX